Tolerability and Safety of Primaquine in Papua New Guinean Children 1 to 10 Years of Age
Open Access
- 1 April 2012
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (4), 2146-2149
- https://doi.org/10.1128/aac.05566-11
Abstract
Primaquine is currently the only drug available for radical cure of Plasmodium vivax and P. ovale liver infection stages, but limited safety data exist for children n = 252) or artesunate (7 days; n = 141) (0.5 mg/kg of body weight) showed that both treatments are well tolerated, do not lead to reductions in hemoglobin levels, and can thus safely be used in children 1 to 10 years of age.Keywords
This publication has 11 references indexed in Scilit:
- Medications and Glucose-6-Phosphate Dehydrogenase DeficiencyDrug Safety, 2010
- In Tanzania, Hemolysis after a Single Dose of Primaquine Coadministered with an Artemisinin Is Not Restricted to Glucose-6-Phosphate Dehydrogenase-Deficient (G6PD A−) IndividualsAntimicrobial Agents and Chemotherapy, 2010
- Differential Patterns of Infection and Disease with P. falciparum and P. vivax in Young Papua New Guinean ChildrenPLOS ONE, 2010
- High sensitivity detection of Plasmodium species reveals positive correlations between infections of different species, shifts in age distribution and reduced local variation in Papua New GuineaMalaria Journal, 2009
- Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparumMalaria Journal, 2008
- Plasmodium vivax and Mixed Infections Are Associated with Severe Malaria in Children: A Prospective Cohort Study from Papua New GuineaPLoS Medicine, 2008
- Glucose-6-phosphate dehydrogenase deficiencyThe Lancet, 2008
- Primaquine Therapy for MalariaClinical Infectious Diseases, 2004
- Can primaquine therapy for vivax malaria be improved?Trends in Parasitology, 2003
- 3. TOXICITY OF PRIMAQUINE IN CAUCASIANSJAMA, 1952